Pharma Management SA
2.5 FTEThe score of Pharma Management shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -51 % Total assets -26 % Headcount (avg FTE) +9 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Pharma Management's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 29 Jul 2026
- Year ended 31 Dec 2024filed on 07 Jul 2025
- Year ended 31 Dec 2023filed on 29 Aug 2024
- Year ended 31 Dec 2022filed on 23 Aug 2023
- Year ended 31 Dec 2021filed on 21 Sep 2022
Pharma Management's financial analysis
- Solvency37.1%sector median: 44.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Pharma Management
Pharma Management's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0451.878.656
- VAT number
- BE0451878656
- Peppol
- Registered · 0208:0451878656 · as of 09 Nov 2026
- Legal form
- SA
- Incorporated
- 13 Jan 1994
- Registered office
- 3400 Landen
- Size
- Micro · 2.5 FTE
- Latest accounts
- 2025 · filed on 29 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Pharma Management (SA) has been based in Landen since 1994, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 376,772 € and equity of €1.18m; its revenue is not published. With 2.5 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 37.1%, below the median of its sector (44.0%).
Companies similar to Pharma Management
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie DE Neef - Duez Retail sale of pharmaceutical products Mons · balance sheet 181,026 €
- GDK Farma Retail sale of pharmaceutical products Grimbergen · balance sheet €3.07m
- Xpharma Retail sale of pharmaceutical products Puurs-Sint-Amands · balance sheet €3.07m
- Extra-Pharma Retail sale of pharmaceutical products Kapellen · balance sheet €3.06m
- VAN Nuffel - DE Vriendt Retail sale of pharmaceutical products Beveren-Kruibeke-Zwijndrecht · balance sheet €2.84m
- Unifarma Retail sale of pharmaceutical products Kortrijk · balance sheet €3.56m
- Les Pharmacies de Gare Retail sale of pharmaceutical products Brussels · balance sheet €2.73m
- Apotheek Van den Broeck Riet Retail sale of pharmaceutical products Ranst · balance sheet €2.67m
Frequently asked questions about Pharma Management
What is the revenue of Pharma Management?
Pharma Management files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Pharma Management?
In Belgium, the VAT number is the company number prefixed with BE: BE0451878656 for Pharma Management, if the company is VAT-registered. Its company number (CBE) is 0451.878.656.
Where is the registered office of Pharma Management?
According to the CBE register, the registered office of Pharma Management is in 3400 Landen.
What is the equity of Pharma Management?
At the close of the 2025 financial year, the equity of Pharma Management amounts to 1,178,008 €, a solvency of 37.1% of total assets.
How many people work at Pharma Management?
2.5 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Pharma Management?
The register lists 3 active mandates at Pharma Management. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Pharma Management
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →